Pharmacology, Toxicology and Pharmaceutical Science
Atrial Fibrillation
100%
Biological Marker
58%
Disease
57%
ST Segment Elevation Myocardial Infarction
50%
Non ST Segment Elevation Myocardial Infarction
50%
Somatomedin Binding Protein 2
50%
Aortic Valve Stenosis
50%
Rivaroxaban
50%
Pulmonary Hypertension
50%
Persistent Atrial Fibrillation
50%
Hospital Mortality
50%
Beta Adrenergic Receptor Blocking Agent
50%
Coronavirinae
50%
Ischemic Cardiomyopathy
50%
microRNA
50%
Heart Infarction
50%
Paroxysmal Atrial Fibrillation
50%
Recurrent Disease
50%
Sudden Cardiac Death
50%
Low Density Lipoprotein Cholesterol
41%
Protein P53
25%
Infarction
25%
Cardiogenic Shock
25%
Ezetimibe
16%
Hydroxymethylglutaryl Coenzyme A Reductase Inhibitor
16%
Small Interfering RNA
16%
Heart Ventricle Remodeling
13%
Heart Muscle Ischemia
8%
Statin (Protein)
8%
Retrospective Study
8%
Antiapoptotic
8%
Prevalence
8%
Monotherapy
8%
Diabetes Mellitus
8%
Congestive Heart Failure
8%
Random Effects Model
8%
Rat Model
8%
Cohort Study
8%
Enzyme-Linked Immunosorbent Assay
8%
Pathophysiology
7%
Prematurity
7%
Atrioventricular Block
6%
Second Degree Atrioventricular Block
6%
Heart Arrhythmia
6%
Bleeding
6%
Cardiovascular Disease
6%
Cardiovascular Risk
6%
Fibroblast Growth Factor 23
5%
Carcinogenicity
5%
Heart Atrium Remodeling
5%
Medicine and Dentistry
Atrial Fibrillation
100%
ST Segment Elevation Myocardial Infarction
50%
Somatomedin Binding Protein 2
50%
Aortic Valve Stenosis
50%
Paroxysmal Atrial Fibrillation
50%
Persistent Atrial Fibrillation
50%
COVID-19
50%
Cardioversion
50%
Biological Marker
50%
Pulmonary Hypertension
50%
Sudden Cardiac Death
50%
Recurrent Disease
50%
Rivaroxaban
50%
Low Density Lipoprotein Cholesterol
41%
Statin
25%
Percutaneous Aortic Valve Replacement
21%
Lung Artery Pressure
21%
Thromboprophylaxis
18%
Secondary Prevention
16%
Ezetimibe
16%
Cardiovascular System
13%
Drug Therapy
8%
Retrospective Study
8%
Diabetes Mellitus
8%
Primary Prevention
8%
Monotherapy
8%
Cardiovascular Condition
7%
Prematurity
7%
Diseases
7%
Pathophysiology
7%
Study Participant
7%
Echocardiography
7%
Arrhythmia
6%
Propensity Score Matching
6%
Bleeding
6%
Major Bleeding
6%
Cardiovascular Risk
6%
Logistic Regression Analysis
6%
Atrioventricular Block
6%
Cardiovascular Disease
6%
Second-Degree Atrioventricular Block
6%
Atrial Fibrillation Therapy
6%
Cardiovascular System
6%
Fibroblast Growth Factor 23
5%
Comorbidity
5%
Adipose Tissue
5%
Endothelial Dysfunction
5%
Growth
5%
Clinical Study
5%
Natriuretic Factor
5%
